Efficacy and tolerability of once-daily mirabegron, a potent and selective &#223;3-adrenoceptor agonist, in patients with overactive bladder – results from a North American Phase III trial

Abstract Category

Detrusor Overactivity

Links
	Abstract 92
	Investigation and Intervention Scientific Podium Poster Session 8
	Wednesday 31st August 2011
	16:55 - 17:00
	Hall P2
	1. NYU Langone Medical Center, Department of Urology, New York, NY, USA, 2. University of Toronto, Division of Urology, Toronto, Canada, 3. Astellas Pharma Global Development, Inc., Biostatistics, Deerfield, IL, USA, 4. Astellas Pharma Global Development, Inc., Global Medical Sciences, Deerfield, IL, USA
Presenter
V Victor Nitti
Abstract PDF Edit Abstract Abstract Centre